Program
irinotecan sucrosofate
Also written as “Irinotecan liposome injection”, “PEP02” and “Irinotecan Liposome Injection”.
Its studies are mostly in Pancreatic Neoplasms · Small Cell Lung Carcinoma · Breast Neoplasms · Esophageal Squamous Cell Carcinoma · Cholangiocarcinoma, led by 9 companies.
Drug pageIrinotecan sucrosofate: every studyMany companies study it; this page follows only the 20 they lead. All 79 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CSPC Pharmaceutical Groupits history only | 50 open or running | phase 2since Jan 18, 2021 | Jul 20, 2020 | none ahead |
| PharmaEngineits history only | 50 open or running | phase 2since Dec 18, 2008 | Dec 18, 2008 | none ahead |
| Ipsenits history only | 40 open or running | phase 3since Mar 9, 2017 | Dec 19, 2012 | none ahead |
| Cardiff Oncologyits history only | 10 open or running | phase 2since Feb 9, 2021 | Feb 9, 2021 | none ahead |
| Jiangsu HengRui Medicineits history only | 10 open or running | phase 1since Sep 29, 2021 | Sep 29, 2021 | none ahead |
| Merrimack Pharmaceuticalsits history only | 10 open or running | phase 3since Dec 14, 2011 | Dec 14, 2011 | none ahead |
| Shanghai Runshi Pharmaceutical Technology | 11 open or running | phase 2since Jul 9, 2024 | Jul 9, 2024 | none ahead |
| SONIRE Therapeuticsits history only | 11 open or running | early phase 1since Jun 5, 2025 | Jun 5, 2025 | Dec 1, 2026early phase 1 · NCT07033689 |
| Sorrento Therapeuticsits history only | 10 open or running | phase 3since Jul 26, 2019 | Jul 26, 2019 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Shanghai Runshi Pharmaceutical Technology only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 9, 2024First study: phase 2 study in Advanced Esophageal Squamous Cell CarcinomaFirst studyNCT06512428 · 138 planned · China
TargetBeta
“DNA topoisomerase I inhibitor”ChEMBL 37, by rule
Other programs on TOP1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Topotecanrule | GlaxoSmithKline | phase 3 | 33 |
Studies
The one study Shanghai Runshi Pharmaceutical Technology leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06512428Advanced Esophageal Squamous Cell Carcinoma · China | 2 | Recruiting | Jan 30, 2026 | 138 |
How it is read
Names in the registry
- “Irinotecan liposome injection”, 5 entries
- “PEP02”, 4 entries
- “Irinotecan Liposome Injection”, 3 entries
- “MM-398”, 2 entries
- “Nanoliposomal irinotecan”, 1 entry
Conditions, from the studies’ own filings
- Pancreatic Neoplasms, 6 studies
- Small Cell Lung Carcinoma, 2 studies
- Breast Neoplasms, 1 study
- Esophageal Squamous Cell Carcinoma, 1 study
- Cholangiocarcinoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.